☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
Kalaris Therapeutics Reverse Merges with AlloVir to Advance Therapies Focusing on Retinal Diseases
November 11, 2024
The Role of CCL17 in Immune Regulation: Unlocking New Therapeutic Possibilities
November 8, 2024
Johnson & Johnson MedTech Reports the US FDA’s Approval of VARIPULSE Pulsed Field Ablation Platform to Treat Atrial Fibrillation
November 8, 2024
Johnson & Johnson MedTech Reports the US FDA’s Approval of VARIPULSE Pulsed Field Ablation Platform to Treat Atrial Fibrillation
November 8, 2024
Know Your Investor: Catalio Capital Management (November’24 Edition)
November 7, 2024
Aditum Bio and Leads Biolabs Launch Oblenio Bio to Advance LBL-051 for Autoimmune Indications
November 7, 2024
GHO Capital Partners and Ampersand Capital Partners Report the Acquisition of Avid Bioservices for ~$1.1B
November 7, 2024
Inocras and Summit Pharmaceuticals International Corporation Join Forces to Advance Healthcare in Japan
November 6, 2024
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
Email
First Name
Last Name
Company Name
Area/Designation
Daily Newsletter
Weekly Newsletter
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.
